Abstract:
Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years. Acute gout is intensely painful and can reduce patients' quality of life. It occurs when the serum uric acid concentration (SUA) rises (hyperuricaemia) and persists above the solubility threshold of monosodium urate (400 micromol/L [6.8 mg/dL]), leading to urate crystal formation that causes arthritis, gouty tophi (nodules) in subcutaneous tissues and renal calculi. The mainstay of treatment for chronic gout is allopurinol, which inhibits xanthine oxidase (an enzyme involved in the production of uric acid in the body). However, this drug has to be stopped in a minority of patients due to rashes or hypersensitivity. Febuxostat (Adenuric - Menarini/Ipsen), another xanthine oxidase inhibitor, is a newly licensed treatment for chronic hyperuricaemia in conditions where urate deposition has occurred. Here we consider its place for patients with gout.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)